Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: a Pilot Study.

Trial Profile

Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: a Pilot Study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms GILEAD
  • Most Recent Events

    • 16 Mar 2017 Status changed from recruiting to discontinued.
    • 08 Aug 2012 Actual initiation date changed from 1 Jan 2012 to Mar 2012 as reported by ClinicalTrials.gov.
    • 08 Aug 2012 Planned End Date changed from 1 Oct 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top